Cyclacel displays its POLO ponies

In 2000, cell cycle specialist Cyclacel Ltd. set up a division to discover and develop cancer genes associated with mitosis and meiosis, based on more than 100 genomic targets regulating cancer cell division in the fruitfly. Since then, there has been little news from the division, which was named Polgen.

Last week, Cyclacel announced that Polgen has developed a series of compounds that inhibit the human Polo-like kinase 1 (Plk1), with some candidates demonstrating high potency at the low nanomolar level. ...